Arbutus to report fourth quarter and year end 2021 financial results and provide corporate update

Warminster, pa., feb. 17, 2022 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its fourth quarter and year end 2021 financial results and corporate update for thursday, march 3, 2022. the schedule for the press release and conference call/webcast are as follows:
ABUS Ratings Summary
ABUS Quant Ranking